Press Releases

Date Title View
Toggle SummaryJuly 16, 2018 GenMark Diagnostics Schedules Second Quarter Financial Results Conference Call for July 30, 2018
CARLSBAD, Calif. , July 16, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its second quarter earnings results after market close on Monday, July 30, 2018. Management will hold a conference call to review the Company's financial performance
View HTML
Toggle SummaryJune 28, 2018 GenMark Diagnostics Announces FDA Submission of its ePlex Blood Culture Identification Gram Positive Panel
First of Three ePlex Molecular Multiplex Panels for the Diagnosis and Management of Bloodstream Infections That Can Lead to Sepsis CARLSBAD, Calif. , June 28, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing
View HTML
Toggle SummaryJune 6, 2018 GenMark Diagnostics to Present at the William Blair 38th Annual Growth Stock Conference
CARLSBAD, Calif. , June 06, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany , will present at the William Blair 38th Annual
View HTML
Toggle SummaryMay 2, 2018 GenMark Diagnostics to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
CARLSBAD, Calif. , May 02, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany , will present at the Bank of America Merrill Lynch
View HTML
Toggle SummaryMay 1, 2018 GenMark Diagnostics Reports First Quarter 2018 Results
CARLSBAD, Calif. , May 01, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2018 .
View HTML
Toggle SummaryApril 17, 2018 GenMark Diagnostics Schedules First Quarter Financial Results Conference Call for May 1, 2018
CARLSBAD, Calif. , April 17, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 1, 2018. Management will hold a conference call to review the Company's financial performance
View HTML
Toggle SummaryFebruary 27, 2018 GenMark Diagnostics Reports Fourth Quarter and Full Year 2017 Results
CARLSBAD, Calif. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and full year ended December 31, 2017 .
View HTML
Toggle SummaryFebruary 21, 2018 GenMark Diagnostics to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that the Company plans to participate in two upcoming investor conferences. March 1, 2018 , GenMark’s management is scheduled to participate in the BTIG Snowbird Healthcare Conference in
View HTML
Toggle SummaryFebruary 13, 2018 GenMark Diagnostics Schedules Fourth Quarter and Full Year 2017 Financial Results Conference Call for February 27, 2018
CARLSBAD, Calif. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter earnings results after market close on Tuesday, February 27, 2018. Management will hold a conference call to review the Company's financial
View HTML
Toggle SummaryJanuary 9, 2018 GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2017
CARLSBAD, Calif. , Jan. 09, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2017 .
View HTML